Drug
Ak138d1
Ak138d1: highest development phase Phase 1/2, developed by Akeso. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK138D1 NCT07623356 | Phase 1/2 | Non-Small Cell Lung Cancer |
| AK138D1 NCT06730386 | Phase 1 | Solid Cancer |
Latest
Follow Ak138d1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.